Domestic bio-venture empresas are achieving major milestones in rapid succession, including nacional e internacional transferencia de tecnologías for innovador new drug pipelines and internacional investigación conjunta initiatives.
The fact that many of these empresas are still early-stage startups receiving gobierno apoyo makes this all the more significant, reaffirming the potential of 'K-BIO' even in challenging nacional e internacional industria conditions.
Además, RudaCure recently transferred its úlcera corneal and daño corneal tratamiento tecnología to Hanlim Pharmaceutical, and Owl Bio entered a strategic asociación with Kyungdong Pharmaceutical to comercializar long-acting injectable drugs.
These bio startups are participants in the Ministry of SMEs and Startups' 'Innovador Field Startup Package Support' programa, sharing the common thread of successfully commercializing their technologies with the backing of gobierno strategic startup apoyo. Since 2020, the ministry ha sido selecting and systematically apoyoing prometedor startups reconocido for their core technological capabilities and crecimiento potential in the three major new industria sectors: system semiconductors, bio-health, and future mobility — with continuous and systematic I+D and comercialización apoyo.
A representative from the Korea Institute of Toxicology, which apoyos bio-health empresas, señaló, "Given the nature of the bio sector where most startups are tecnología-based, the reality is that most empresas face greater difficulties in the comercialización stage after founding," adding, "In this context, the ability to quickly bring innovador technologies to mercado using gobierno comercialización apoyo as a catalyst ha sido the key to achieving early resultados."
K-BIO Ventures Equipped with Technological Prowess Score Big Day After Day: Herald Economy